19 September 2022 : Clinical Research
Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
Zhen Yuan12ABCDEF, Shuyuan Wang12ABCDEF, Kemin Ni
12ACDF, Yixiang Zhan12ACDF, Hong Ma1BDF, Xinyu Liu13ABC, Ran Xin 2ABC, Xingyu Zhou2BC, Zhaoce Liu12BC, Xuanzhu Zhao14BC, Xin Yin2BC, Hangyu Ping2BC, Yaohong Liu2BC, Wanting Wang4BC, Suying Yan4BC, Qiurong Han4BC, Wei Cui 5CD, Xipeng Zhang167ADF, Qinghuai Zhang167ABCD, Chunze Zhang167ABCDEFG*
DOI: 10.12659/MSM.937757
Med Sci Monit 2022; 28:e937757
Table 1 Baseline characteristics of patients with stage II–III colorectal cancer.
| Total number (n=426) | Preoperative mSEPT9 (n=348) | Postoperative mSEPT9 (n=339) | Longitudinal mSETP9 (n=426) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive (n=173) | Negative (n=175) | p value | Positive (n=60) | Negative (n=279) | p value | Positive (n=110) | Negative (n=316) | p value | ||
|  ≤60 years | 186 (43.7) | 79 (45.7) | 78 (44.6) | 0.914 | 21 (35) | 127 (45.5) | 0.153 | 36 (32.7) | 150 (47.5) | 0.008 |
|  >60 years | 240 (56.3) | 94 (54.3) | 97 (55.4) | 39 (65) | 152 (54.5) | 74 (67.3) | 166 (52.5) | |||
|  Female | 173 (40.6) | 72 (41.6) | 71 (40.6) | 0.913 | 25 (41.7) | 115 (41.2) | 1.000 | 39 (35.5) | 134 (42.4) | 0.216 |
|  Male | 253 (59.4) | 101 (58.4) | 104 (59.4) | 35 (58.3) | 164 (58.8) | 71 (64.5) | 182 (57.6) | |||
|  Well/moderate | 277 (65.0) | 113 (65.3) | 110 (62.9) | 0.656 | 31 (51.7) | 183 (65.6) | 0.055 | 62 (56.4) | 215 (68) | 0.036 |
|  Poor | 149 (35.0) | 60 (34.7) | 65 (37.1) | 29 (48.3) | 96 (34.4) | 48 (43.6) | 101 (32) | |||
|  Adenocarcinoma | 393 (92.3) | 164 (94.8) | 154 (88) | 0.034 | 53 (88.3) | 256 (91.8) | 0.450 | 100 (90.9) | 293 (92.7) | 0.538 |
|  Other types | 33 (7.7) | 9 (5.2) | 21 (12) | 7 (11.7) | 23 (8.2) | 10 (9.1) | 23 (7.3) | |||
|  II | 180 (42.3) | 78 (45.1) | 74 (42.3) | 0.666 | 18 (30.0) | 122 (43.7) | 0.060 | 36 (32.7) | 144 (45.6) | 0.019 |
|  III | 246 (57.7) | 95 (54.9) | 101 (57.7) | 42 (70.0) | 157 (56.3) | 74 (67.3) | 172 (54.4) | |||
|  pT1 | 1 (0.2) | 0 (0.0) | 1 (0.6) | 0.190 | 0 (0.0) | 1 (0.4) | 0.899 | 0 (0.0) | 1 (0.3) | 0.400 |
|  pT2 | 19 (4.5) | 3 (1.7) | 15 (8.6) | 3 (5.0) | 12 (4.3) | 5 (4.5) | 14 (4.4) | |||
|  pT3 | 262 (61.5) | 111 (64.2) | 103 (58.9) | 37 (61.7) | 171 (61.3) | 64 (58.2) | 198 (62.7) | |||
|  pT4 | 144 (33.8) | 59 (34.1) | 56 (32.0) | 20 (33.3) | 95 (34.1) | 41 (37.3) | 103 (32.6) | |||
|  pN0 | 180 (42.3) | 78 (45.1) | 74 (42.3) | 0.398 | 18 (30.0) | 122 (43.7) | 0.031 | 36 (32.7) | 144 (45.6) | 0.030 |
|  pN1 | 176 (41.3) | 71 (41) | 69 (39.4) | 28 (46.7) | 115 (41.2) | 53 (48.2) | 123 (38.9) | |||
|  pN2 | 70 (16.4) | 24 (13.9) | 32 (18.3) | 14 (23.3) | 42 (15.1) | 21 (19.1) | 49 (15.5) | |||
|  Rectum | 227 (53.3) | 86 (49.7) | 94 (53.7) | 0.524 | 31 (51.7) | 138 (49.5) | 0.718 | 56 (50.9) | 171 (54.1) | 0.781 |
|  Left colon | 115 (27.0) | 54 (31.2) | 45 (25.7) | 14 (23.3) | 79 (28.3) | 30 (27.3) | 85 (26.9) | |||
|  Right colon | 84 (19.7) | 33 (19.1) | 36 (20.6) | 15 (25.0) | 62 (22.2) | 24 (21.8) | 60 (19.0) | |||
|  No ACT | 26 (6.1) | 13 (7.5) | 10 (5.7) | 0.653 | 4 (6.7) | 11 (3.9) | 1.000 | 6 (5.5) | 20 (6.3) | 0.220 |
|  ACT | 400 (93.9) | 160 (92.5) | 165 (94.3) | 56 (93.3) | 268 (96.1) | 104 (94.5) | 296 (93.7) | |||
|  None | 26 (6.1) | 13 (7.5) | 10 (5.8) | 0.649 | 4 (6.7) | 11 (3.9) | 0.538 | 6 (5.5) | 20 (6.3) | 0.399 |
|  FOLFOX | 161 (37.8) | 72 (41.6) | 73 (41.7) | 30 (50.0) | 112 (40.1) | 50 (45.5) | 111 (35.1) | |||
|  FOLFIRI | 36 (8.5) | 13 (7.5) | 10 (5.7) | 4 (6.7) | 25 (9.0) | 7 (6.4) | 29 (9.2) | |||
|  CAPEOX | 177 (41.5) | 60 (34.7) | 72 (41.1) | 20 (33.3) | 119 (42.7) | 41 (37.2) | 136 (43.0) | |||
|  Single agent | 26 (6.1) | 15 (8.7) | 10 (5.7) | 2 (3.3) | 12 (4.3) | 6 (5.5) | 20 (6.3) | |||
|  None | 26 (6.1) | 13 (7.5) | 10 (5.7) | 0.858 | 2 (6.7) | 11 (3.9) | 0.366 | 6 (5.5) | 20 (6.3) | 0.687 |
|  3 months | 148 (34.7) | 57 (32.9) | 61 (34.9) | 25 (41.7) | 94 (33.7) | 41 (37.3) | 107 (33.9) | |||
|  6 months | 253 (59.2) | 103 (59.5) | 104 (59.4) | 31 (51.7) | 174 (62.4) | 63 (57.3) | 189 (59.8) | |||
|  Yes | 50 (11.7) | 22 (12.7) | 19 (10.9) | 0.621 | 21 (35) | 19 (6.8) | <0.001 | 36 (32.7) | 14 (4.4) | <0.001 |
|  No | 376 (88.3) | 151 (87.3) | 156 (89.1) | 39 (65) | 260 (93.2) | 74 (67.3) | 302 (95.6) | |||
|  Locoregional only | 9/50 (12.0) | 3/22 (13.6) | 6/19 (31.4) | 0.260 | 3/21 (14.3) | 4/19 (21.1) | 0.689 | 6/36 (16.7) | 3/14 (21.4) | 0.697 |
|  Distant±locoregional | 41/50 (82.0) | 19/22 (86.4) | 13/19 (68.4) | 18/21 (85.7) | 15/19 (78.9) | 30/36 (83.3) | 11/14 (78.6) | |||
|  6–12 months | 101 (23.7) | 49 (28.3) | 49 (28) | 0.158 | 17 (28.3) | 81 (29) | 0.351 | 22 (20) | 79 (25) | 0.677 |
|  12–24 months | 276 (64.8) | 120 (69.4) | 113 (64.6) | 36 (60) | 188 (67.4) | 73 (66.4) | 203 (64.2) | |||
|  24–36 months | 42 (9.9) | 4 (2.3) | 12 (6.9) | 7 (11.7) | 9 (3.2) | 13 (11.8) | 29 (9.2) | |||
|  >36 months | 7 (1.6) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.4) | 2 (1.8) | 5 (1.6) | |||
| mSEPT9 – methylated Septin9; ACT – adjuvant chemotherapy. | ||||||||||